EMERGENT BIOSOLUTIONS INC. Operating Income
EMERGENT BIOSOLUTIONS INC. (EBS) reported Operating Income of -$125.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-06
- EMERGENT BIOSOLUTIONS INC. operating income (loss) for the quarter ending 2026-06-30 was -$125.10M, a 7918.75% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. operating income (loss) for the quarter ending 2026-03-31 was $10.50M, a 78.96% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. operating income (loss) for the quarter ending 2025-12-31 was -$27.90M.
- EMERGENT BIOSOLUTIONS INC. operating income (loss) for the quarter ending 2025-09-30 was $76.50M, a 18.60% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. operating income (loss) for fiscal 2025 was $100.10M.
- EMERGENT BIOSOLUTIONS INC. operating income (loss) for fiscal 2024 was -$108.70M.
- EMERGENT BIOSOLUTIONS INC. operating income (loss) for fiscal 2023 was -$726.40M.
- EMERGENT BIOSOLUTIONS INC. operating income (loss) for fiscal 2022 was -$170.00M, a 149.79% decline from fiscal 2021.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$125.10M 10-Q · filed 2026-08-06 | -$114.60M 10-Q · filed 2026-08-06 | -$142.50M derived: sum of 3 quarters · filed 2026-08-06 | -$66.00M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $10.50M 10-Q · filed 2026-05-01 | -$17.40M derived: sum of 2 quarters · filed 2026-05-01 | $59.10M derived: sum of 3 quarters · filed 2026-05-01 | $60.70M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$27.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $48.60M derived: sum of 2 quarters · filed 2026-02-27 | $50.20M derived: sum of 3 quarters · filed 2026-08-06 | $100.10M 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | $76.50M 10-Q · filed 2025-10-30 | $78.10M derived: sum of 2 quarters · filed 2026-08-06 | $128.00M 10-Q · filed 2025-10-30 | $118.50M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $1.60M 10-Q · filed 2026-08-06 | $51.50M 10-Q · filed 2026-08-06 | $42.00M derived: sum of 3 quarters · filed 2026-08-06 | $106.50M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $49.90M 10-Q · filed 2026-05-01 | $40.40M derived: sum of 2 quarters · filed 2026-05-01 | $104.90M derived: sum of 3 quarters · filed 2026-05-01 | -$98.60M derived: sum of 4 quarters · filed 2026-05-01 | ||||
| 2024-12-31 | -$9.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $55.00M derived: sum of 2 quarters · filed 2026-02-27 | -$148.50M derived: sum of 3 quarters · filed 2026-02-27 | -$108.70M 10-K · filed 2026-02-27 | ||||
| 2024-09-30 | $64.50M 10-Q · filed 2025-10-30 | -$139.00M derived: sum of 2 quarters · filed 2025-10-30 | -$99.20M 10-Q · filed 2025-10-30 | -$143.00M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-06-30 | -$203.50M 10-Q · filed 2025-08-07 | -$163.70M 10-Q · filed 2025-08-07 | -$207.50M derived: sum of 3 quarters · filed 2026-02-27 | -$449.60M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-03-31 | $39.80M 10-Q · filed 2025-05-08 | -$4.00M derived: sum of 2 quarters · filed 2026-02-27 | -$246.10M derived: sum of 3 quarters · filed 2026-02-27 | -$539.00M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2023-12-31 | -$43.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$285.90M derived: sum of 2 quarters · filed 2026-02-27 | -$578.80M derived: sum of 3 quarters · filed 2026-02-27 | -$726.40M 10-K · filed 2026-02-27 | ||||
| 2023-09-30 | -$242.10M 10-Q · filed 2024-11-07 | -$535.00M derived: sum of 2 quarters · filed 2024-11-07 | -$682.60M 10-Q · filed 2024-11-07 | -$737.90M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$292.90M 10-Q · filed 2024-08-07 | -$440.50M 10-Q · filed 2024-08-07 | -$441.00M 10-Q · filed 2023-08-09 | -$495.80M derived: sum of 3 quarters · filed 2024-08-07 | -$541.10M derived: sum of 4 quarters · filed 2024-08-07 | |||
| 2023-03-31 | -$147.60M 10-Q · filed 2024-05-02 | -$148.10M 10-Q · filed 2023-05-10 | -$202.90M derived: sum of 2 quarters · filed 2024-05-02 | -$248.20M derived: sum of 3 quarters · filed 2024-05-02 | -$324.50M derived: sum of 4 quarters · filed 2024-05-02 | |||
| 2022-12-31 | -$55.30M 10-K/A · filed 2023-12-11 | -$100.60M derived: sum of 2 quarters · filed 2023-12-11 | -$176.90M derived: sum of 3 quarters · filed 2023-12-11 | -$170.00M 10-K · filed 2025-03-04 | -$172.70M 10-K · filed 2023-03-01 | |||
| 2022-09-30 | -$45.30M 10-K/A · filed 2023-12-11 | -$42.00M 10-Q · filed 2022-11-09 | -$121.60M derived: sum of 2 quarters · filed 2023-12-11 | -$114.70M 10-Q · filed 2023-12-11 | -$107.60M 10-Q · filed 2022-11-09 | $172.10M derived: sum of 4 quarters · filed 2023-12-11 | ||
| 2022-06-30 | -$76.30M 10-K/A · filed 2023-12-11 | -$72.00M 10-Q · filed 2022-08-02 | -$65.60M 10-Q · filed 2023-08-09 | $217.40M derived: sum of 3 quarters · filed 2023-12-11 | $172.70M derived: sum of 4 quarters · filed 2023-12-11 | |||
| 2022-03-31 | $6.90M 10-K/A · filed 2023-12-11 | $6.40M 10-Q · filed 2022-04-29 | $293.70M derived: sum of 2 quarters · filed 2023-12-11 | $249.00M derived: sum of 3 quarters · filed 2023-12-11 | $256.10M derived: sum of 4 quarters · filed 2023-12-11 | |||
| 2021-12-31 | $286.80M 10-K/A · filed 2023-12-11 | $242.10M derived: sum of 2 quarters · filed 2023-12-11 | $249.20M derived: sum of 3 quarters · filed 2023-12-11 | $341.40M 10-K · filed 2024-03-08 | $352.60M 10-K · filed 2022-02-25 | |||
| 2021-09-30 | -$44.70M 10-K/A · filed 2023-12-11 | -$34.70M 10-Q · filed 2021-11-05 | -$37.60M derived: sum of 2 quarters · filed 2023-12-11 | $75.20M 10-Q · filed 2022-11-09 | $312.70M derived: sum of 4 quarters · filed 2023-12-11 | |||
| 2021-06-30 | $7.10M 10-K/A · filed 2023-12-11 | $14.50M 10-Q · filed 2021-07-30 | $109.90M 10-Q · filed 2022-08-02 | $357.40M derived: sum of 3 quarters · filed 2023-12-11 | $418.70M derived: sum of 4 quarters · filed 2023-12-11 | |||
| 2021-03-31 | $92.20M 10-K/A · filed 2023-12-11 | $95.40M 10-Q · filed 2021-04-30 | $350.30M derived: sum of 2 quarters · filed 2023-12-11 | $411.60M derived: sum of 3 quarters · filed 2023-12-11 | $537.60M derived: sum of 4 quarters · filed 2023-12-11 | |||
| 2020-12-31 | $258.10M 10-K · filed 2021-02-19 | $319.40M derived: sum of 2 quarters · filed 2021-11-05 | $445.40M derived: sum of 3 quarters · filed 2021-11-05 | $438.50M 10-K/A · filed 2023-12-11 | $433.80M 10-K · filed 2021-02-19 | |||
| 2020-09-30 | $61.30M 10-Q · filed 2021-11-05 | $187.30M derived: sum of 2 quarters · filed 2021-11-05 | $175.70M 10-Q · filed 2021-11-05 | $253.50M derived: sum of 4 quarters · filed 2021-11-05 | ||||
| 2020-06-30 | $126.00M 10-Q · filed 2021-07-30 | $114.40M 10-Q · filed 2021-07-30 | $192.20M derived: sum of 3 quarters · filed 2021-07-30 | $262.90M derived: sum of 4 quarters · filed 2021-07-30 | ||||
| 2020-03-31 | -$11.60M 10-Q · filed 2021-04-30 | $66.20M derived: sum of 2 quarters · filed 2021-04-30 | $136.90M derived: sum of 3 quarters · filed 2021-04-30 | $129.90M derived: sum of 4 quarters · filed 2021-04-30 | ||||
| 2019-12-31 | $77.80M 10-K · filed 2021-02-19 | $148.50M derived: sum of 2 quarters · filed 2021-02-19 | $141.50M derived: sum of 3 quarters · filed 2021-02-19 | $114.10M 10-K · filed 2022-02-25 | ||||
| 2019-09-30 | $70.70M 10-K · filed 2021-02-19 | $63.70M derived: sum of 2 quarters · filed 2021-02-19 | $36.40M 10-Q · filed 2020-11-06 | $47.50M derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2019-06-30 | -$7.00M 10-K · filed 2021-02-19 | -$34.40M 10-Q · filed 2020-07-31 | -$23.20M derived: sum of 3 quarters · filed 2021-02-19 | -$1.90M derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2019-03-31 | -$27.40M 10-K · filed 2021-02-19 | -$27.20M 10-Q · filed 2019-05-08 | -$16.20M derived: sum of 2 quarters · filed 2021-02-19 | $5.10M derived: sum of 3 quarters · filed 2021-02-19 | $71.90M derived: sum of 4 quarters · filed 2021-02-19 | |||
| 2018-12-31 | $11.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $32.50M derived: sum of 2 quarters · filed 2021-02-19 | $99.30M derived: sum of 3 quarters · filed 2021-02-19 | $89.80M 10-K · filed 2021-02-19 | ||||
| 2018-09-30 | $21.30M 10-Q · filed 2019-11-07 | $21.31M 10-Q · filed 2018-11-02 | $88.10M derived: sum of 2 quarters · filed 2019-11-07 | $78.60M 10-Q · filed 2019-11-07 | $78.60M 10-Q · filed 2018-11-02 | $131.69M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-06-30 | $66.80M 10-Q · filed 2019-08-02 | $66.78M 10-Q · filed 2018-08-03 | $57.30M 10-Q · filed 2019-08-02 | $57.29M 10-Q · filed 2018-08-03 | $110.39M derived: sum of 3 quarters · filed 2020-02-25 | $158.16M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-03-31 | -$9.50M 10-Q · filed 2019-05-08 | -$9.48M 10-Q · filed 2018-05-04 | $43.59M derived: sum of 2 quarters · filed 2020-02-25 | $91.36M derived: sum of 3 quarters · filed 2020-02-25 | $99.89M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2017-12-31 | $53.09M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $100.86M derived: sum of 2 quarters · filed 2020-02-25 | $109.39M derived: sum of 3 quarters · filed 2020-02-25 | $124.30M 10-K · filed 2020-02-25 | $124.28M 10-K · filed 2018-02-23 | |||
| 2017-09-30 | $47.77M 10-Q · filed 2018-11-02 | $56.30M derived: sum of 2 quarters · filed 2018-11-02 | $71.21M 10-Q · filed 2018-11-02 | $122.11M derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-06-30 | $8.53M 10-Q · filed 2018-08-03 | $23.44M 10-Q · filed 2018-08-03 | $74.35M derived: sum of 3 quarters · filed 2019-02-22 | $109.82M derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-03-31 | $14.91M 10-Q · filed 2018-05-04 | $65.82M derived: sum of 2 quarters · filed 2019-02-22 | $101.30M derived: sum of 3 quarters · filed 2019-02-22 | $99.25M derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2016-12-31 | $50.91M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $86.39M derived: sum of 2 quarters · filed 2019-02-22 | $84.34M derived: sum of 3 quarters · filed 2019-02-22 | $105.50M 10-K · filed 2019-02-22 | $105.52M 10-K · filed 2017-02-28 | |||
| 2016-09-30 | $35.48M 10-Q · filed 2017-11-03 | $33.44M derived: sum of 2 quarters · filed 2017-11-03 | $54.59M 10-Q · filed 2017-11-03 | $104.48M derived: sum of 4 quarters · filed 2017-11-03 | ||||
| 2016-06-30 | -$2.04M 10-Q · filed 2017-08-04 | -$13.62M 10-Q · filed 2016-08-05 | $19.11M 10-Q · filed 2017-08-04 | -$5.06M 10-Q · filed 2016-08-05 | $69.01M derived: sum of 3 quarters · filed 2017-08-04 | $132.17M derived: sum of 4 quarters · filed 2017-08-04 | ||
| 2016-03-31 | $21.16M 10-Q · filed 2017-05-05 | $8.56M 10-Q · filed 2016-05-06 | $71.05M derived: sum of 2 quarters · filed 2017-05-05 | $134.21M derived: sum of 3 quarters · filed 2017-05-05 | $155.66M derived: sum of 4 quarters · filed 2017-05-05 | |||
| 2015-12-31 | $49.89M 10-K · filed 2016-02-29 | $113.05M derived: sum of 2 quarters · filed 2016-11-09 | $134.50M derived: sum of 3 quarters · filed 2016-11-09 | $141.51M 10-K · filed 2018-02-23 | $96.04M 10-K · filed 2016-02-29 | |||
| 2015-09-30 | $63.16M 10-Q · filed 2016-11-09 | $53.01M 10-Q · filed 2015-11-06 | $84.61M derived: sum of 2 quarters · filed 2016-11-09 | $76.37M 10-Q · filed 2016-11-09 | $46.15M 10-Q · filed 2015-11-06 | $100.92M derived: sum of 4 quarters · filed 2016-11-09 | ||
| 2015-06-30 | $21.45M 10-Q · filed 2016-08-05 | -$6.86M 10-Q · filed 2016-08-05 | $37.76M derived: sum of 3 quarters · filed 2016-08-05 | $68.79M derived: sum of 4 quarters · filed 2016-08-05 | ||||
| 2015-03-31 | -$28.31M 10-Q · filed 2016-05-06 | $16.31M derived: sum of 2 quarters · filed 2016-05-06 | $47.34M derived: sum of 3 quarters · filed 2016-05-06 | $55.20M derived: sum of 4 quarters · filed 2016-05-06 | ||||
| 2014-12-31 | $44.62M 10-K · filed 2016-02-29 | $75.65M derived: sum of 2 quarters · filed 2016-02-29 | $83.51M derived: sum of 3 quarters · filed 2016-02-29 | $89.19M 10-K · filed 2017-02-28 | $58.06M 10-K · filed 2015-03-09 | |||
| 2014-09-30 | $31.03M 10-K · filed 2016-02-29 | $38.89M derived: sum of 2 quarters · filed 2016-02-29 | $13.44M 10-Q · filed 2015-11-06 | $36.73M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $7.86M 10-K · filed 2016-02-29 | -$17.60M 10-Q · filed 2015-08-06 | $5.70M derived: sum of 3 quarters · filed 2016-02-29 | $23.84M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | -$25.46M 10-K · filed 2016-02-29 | -$2.17M derived: sum of 2 quarters · filed 2016-02-29 | $15.98M derived: sum of 3 quarters · filed 2016-02-29 | $30.69M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $23.29M 10-K · filed 2015-03-09 | $41.44M derived: sum of 2 quarters · filed 2015-03-09 | $56.15M derived: sum of 3 quarters · filed 2015-03-09 | $42.80M 10-K · filed 2016-02-29 | ||||
| 2013-09-30 | $18.15M 10-K · filed 2015-03-09 | $32.86M derived: sum of 2 quarters · filed 2015-03-09 | $19.51M 10-Q · filed 2014-11-10 | $43.54M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2013-06-30 | $14.71M 10-K · filed 2015-03-09 | $1.36M 10-Q · filed 2014-08-08 | $25.40M derived: sum of 3 quarters · filed 2015-03-09 | $35.21M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2013-03-31 | -$13.35M 10-K · filed 2015-03-09 | $10.69M derived: sum of 2 quarters · filed 2015-03-09 | $20.50M derived: sum of 3 quarters · filed 2015-03-09 | $29.16M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2012-12-31 | $24.04M 10-K · filed 2014-03-10 | $33.85M derived: sum of 2 quarters · filed 2014-03-10 | $42.51M derived: sum of 3 quarters · filed 2014-03-10 | $29.97M 10-K · filed 2015-03-09 | ||||
| 2012-09-30 | $9.82M 10-K · filed 2014-03-10 | $18.47M derived: sum of 2 quarters · filed 2014-03-10 | $5.93M 10-Q · filed 2013-11-08 | $51.92M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2012-06-30 | $8.65M 10-K · filed 2014-03-10 | -$3.88M 10-Q · filed 2013-08-06 | $42.10M derived: sum of 3 quarters · filed 2014-03-10 | $43.51M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2012-03-31 | -$12.54M 10-K · filed 2014-03-10 | $33.45M derived: sum of 2 quarters · filed 2014-03-10 | $34.86M derived: sum of 3 quarters · filed 2014-03-10 | $55.07M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2011-12-31 | $45.99M 10-K · filed 2013-03-08 | $47.40M derived: sum of 2 quarters · filed 2013-03-08 | $67.61M derived: sum of 3 quarters · filed 2013-03-08 | $32.10M 10-K · filed 2014-03-10 | ||||
| 2011-09-30 | $1.41M 10-K · filed 2013-03-08 | $21.61M derived: sum of 2 quarters · filed 2013-03-08 | -$13.89M 10-Q · filed 2012-11-01 | $21.07M derived: sum of 4 quarters · filed 2013-03-08 | ||||
| 2011-06-30 | $20.21M 10-K · filed 2013-03-08 | -$15.30M 10-Q · filed 2012-08-03 | $19.66M derived: sum of 3 quarters · filed 2013-03-08 | $40.27M derived: sum of 4 quarters · filed 2013-03-08 | ||||
| 2011-03-31 | -$35.51M 10-K · filed 2013-03-08 | -$543.00K derived: sum of 2 quarters · filed 2013-03-08 | $20.06M derived: sum of 3 quarters · filed 2013-03-08 | $34.87M derived: sum of 4 quarters · filed 2013-03-08 | ||||
| 2010-12-31 | $34.96M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-08 | $55.57M derived: sum of 2 quarters · filed 2013-03-08 | $70.38M derived: sum of 3 quarters · filed 2013-03-08 | $73.56M 10-K · filed 2013-03-08 | ||||
| 2010-09-30 | $20.61M 10-Q · filed 2011-11-04 | $35.42M derived: sum of 2 quarters · filed 2011-11-04 | $38.59M 10-Q · filed 2011-11-04 | |||||
| 2010-06-30 | $14.81M 10-Q · filed 2011-08-05 | $17.99M 10-Q · filed 2011-08-05 | ||||||
| 2009-12-31 | $40.15M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |